Chinese state-owned companies seeking to buy European assets are going to face greater regulatory scrutiny, following a landmark European Commission decision.
In its review of a proposed joint venture between France’s EDF and state-owned China General Nuclear Power, the commission — which has exclusive power over antitrust issues in the EU — ruled that CGN was not independent from China’s central administrator for state-owned enterprises. As a result, it decided that it did have the power to decide whether the deal should be cleared. It meant that the commission did not consider only CGN’s own revenue, but the combined revenue of all Chinese energy SOEs when considering whether the deal came under its jurisdiction.
This approach bumped CGN’s turnover above the minimum EU threshold for merger clearance, a warning shot for other Chinese SOEs that may be considering buying assets in Europe, and were not anticipating needing to obtain a regulatory green light.
The commission generally reviews a merger only if each party to it has more than €250m in sales in the EU. CGN’s turnover, alone, did not cross that threshold, but the Chinese energy SOEs as a whole do breach that level.
Full Content: Business Day
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas